Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- PMID: 19554337
- DOI: 10.1007/s00401-009-0561-9
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Abstract
Somatic mutations in the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase have been shown in the majority of astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III. IDH2 encoding mitochondrial NADP+-dependent isocitrate dehydrogenase is also mutated in these tumors, albeit at much lower frequencies. Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors. To determine mutation types and their frequencies, we examined 1,010 diffuse gliomas. We detected 716 IDH1 mutations and 31 IDH2 mutations. We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III. We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities. IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors. In addition, patients with anaplastic glioma harboring IDH1 mutations were on average 6 years younger than those without these alterations.
Similar articles
-
Analysis of the IDH1 codon 132 mutation in brain tumors.Acta Neuropathol. 2008 Dec;116(6):597-602. doi: 10.1007/s00401-008-0455-2. Epub 2008 Nov 5. Acta Neuropathol. 2008. PMID: 18985363
-
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.Acta Neuropathol. 2010 Dec;120(6):707-18. doi: 10.1007/s00401-010-0781-z. Epub 2010 Nov 19. Acta Neuropathol. 2010. PMID: 21088844
-
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.Acta Neuropathol. 2011 Feb;121(2):241-52. doi: 10.1007/s00401-010-0770-2. Epub 2010 Nov 11. Acta Neuropathol. 2011. PMID: 21069360
-
Glioma-derived mutations in IDH: from mechanism to potential therapy.Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. doi: 10.1016/j.bbrc.2010.05.115. Epub 2010 May 27. Biochem Biophys Res Commun. 2010. PMID: 20510884 Review.
-
IDH mutations in glioma and acute myeloid leukemia.Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Trends Mol Med. 2010. PMID: 20692206 Review.
Cited by
-
The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.Oncol Res. 2024 May 23;32(6):1037-1045. doi: 10.32604/or.2024.051112. eCollection 2024. Oncol Res. 2024. PMID: 38827324 Free PMC article.
-
Frequency of IDH1 mutation in adult-type diffuse astrocytic gliomas in a tertiary hospital in Kenya.Front Med (Lausanne). 2024 Feb 19;11:1305714. doi: 10.3389/fmed.2024.1305714. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38444421 Free PMC article.
-
DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma.Epigenetics. 2024 Dec;19(1):2318506. doi: 10.1080/15592294.2024.2318506. Epub 2024 Mar 5. Epigenetics. 2024. PMID: 38439715 Free PMC article.
-
Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).Sovrem Tekhnologii Med. 2023;15(3):61-71. doi: 10.17691/stm2023.15.3.07. Epub 2023 May 28. Sovrem Tekhnologii Med. 2023. PMID: 38435477 Free PMC article. Review.
-
The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.J Neurooncol. 2024 Mar;167(1):75-88. doi: 10.1007/s11060-024-04563-z. Epub 2024 Feb 16. J Neurooncol. 2024. PMID: 38363490 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous